These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 19523490)

  • 1. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):1-31. PubMed ID: 19523490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.
    Nikolaus S; Antke C; Müller HW
    Behav Brain Res; 2009 Dec; 204(1):32-66. PubMed ID: 19523495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.
    Nikolaus S; Antke C; Kley K; Poeppel TD; Hautzel H; Schmidt D; Müller HW
    Rev Neurosci; 2007; 18(6):439-72. PubMed ID: 18330212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders.
    Gerasimou GP; Aggelopoulou TC; Costa DC; Gotzamani-Psarrakou A
    Nucl Med Rev Cent East Eur; 2006; 9(2):147-53. PubMed ID: 17304479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals.
    Nikolaus S; Larisch R; Beu M; Antke C; Kley K; Forutan F; Wirrwar A; Müller HW
    Rev Neurosci; 2007; 18(6):473-504. PubMed ID: 18330213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
    Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
    Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.
    Court JA; Piggott MA; Lloyd S; Cookson N; Ballard CG; McKeith IG; Perry RH; Perry EK
    Neuroscience; 2000; 98(1):79-87. PubMed ID: 10858614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia.
    Prajjwal P; Kolanu ND; Reddy YB; Ahmed A; Marsool MDM; Santoshi K; Pattani HH; John J; Chandrasekar KK; Hussin OA
    Health Sci Rep; 2024 Apr; 7(4):e2019. PubMed ID: 38562616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders.
    King AE; Mintz J; Royall DR
    Mov Disord; 2011 Jun; 26(7):1218-24. PubMed ID: 21480373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships.
    Snowden JS; Thompson JC; Stopford CL; Richardson AM; Gerhard A; Neary D; Mann DM
    Brain; 2011 Sep; 134(Pt 9):2478-92. PubMed ID: 21840888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases.
    Sajjadi SA; Acosta-Cabronero J; Patterson K; Diaz-de-Grenu LZ; Williams GB; Nestor PJ
    Brain; 2013 Jul; 136(Pt 7):2253-61. PubMed ID: 23729473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of positron emission tomography imaging in movement disorders.
    Bohnen NI; Frey KA
    Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of atypical Parkinson syndromes.
    Höglinger GU; Kassubek J; Csoti I; Ehret R; Herbst H; Wellach I; Winkler J; Jost WH
    J Neural Transm (Vienna); 2017 Aug; 124(8):997-1004. PubMed ID: 28243754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and Psychiatric Disturbances in Parkinsonian Syndromes.
    Zweig RM; Disbrow EA; Javalkar V
    Neurol Clin; 2016 Feb; 34(1):235-46. PubMed ID: 26614001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
    Pimlott SL; Piggott M; Owens J; Greally E; Court JA; Jaros E; Perry RH; Perry EK; Wyper D
    Neuropsychopharmacology; 2004 Jan; 29(1):108-16. PubMed ID: 12955099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.